61 related articles for article (PubMed ID: 27565268)
1. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
2. The NHS: assessing new technologies, NICE and value for money.
Stevens A; Chalkidou K; Littlejohns P
Clin Med (Lond); 2011 Jun; 11(3):247-50. PubMed ID: 21902077
[TBL] [Abstract][Full Text] [Related]
3. The Debrisoft(®) Monofilament Debridement Pad for Use in Acute or Chronic Wounds: A NICE Medical Technology Guidance.
Meads C; Lovato E; Longworth L
Appl Health Econ Health Policy; 2015 Dec; 13(6):583-94. PubMed ID: 26315567
[TBL] [Abstract][Full Text] [Related]
4. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
Hale G; Morris J; Barker-Yip J
J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
[No Abstract] [Full Text] [Related]
5. Pharmacoeconomics: NICE's approach to decision-making.
Rawlins M; Barnett D; Stevens A
Br J Clin Pharmacol; 2010 Sep; 70(3):346-9. PubMed ID: 20716233
[No Abstract] [Full Text] [Related]
6. Implementing NICE clinical guidelines on Parkinson's disease.
Ryton BA; Liddle BJ
Clin Med (Lond); 2009 Oct; 9(5):436-40. PubMed ID: 19886102
[TBL] [Abstract][Full Text] [Related]
7. Problems with NICE's severity weights.
Hausman DM
Soc Sci Med; 2024 May; 348():116833. PubMed ID: 38636210
[TBL] [Abstract][Full Text] [Related]
8. The NHS: assessing new technologies, NICE and value for money.
Patel M
Clin Med (Lond); 2011 Oct; 11(5):508; author reply 508-9. PubMed ID: 22034723
[No Abstract] [Full Text] [Related]
9. Ecstasy and equasy.
Coemgenus
Clin Med (Lond); 2010 Feb; 10(1):101-2. PubMed ID: 20408325
[No Abstract] [Full Text] [Related]
10. A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations.
Wang J; Pouwels X; Ramaekers B; Frederix G; van Lieshout C; Hoogenveen R; Li X; de Wit GA; Joore M; Koffijberg H; van Giessen A; Knies S; Feenstra T;
Pharmacoeconomics; 2024 Jul; 42(7):797-810. PubMed ID: 38613660
[TBL] [Abstract][Full Text] [Related]
11. An investment case analysis for the prevention and treatment of adolescent mental disorders and suicide in England.
Jackson-Morris A; Meyer CL; Morgan A; Stelmach R; Jamison L; Currie C
Eur J Public Health; 2024 Feb; 34(1):107-113. PubMed ID: 37997372
[TBL] [Abstract][Full Text] [Related]
12. Ensuring quality in contextualised cancer management guidelines for resource-constraint settings: using a systematic approach.
Sengar M; Pramesh CS; Mehndiratta A; Shah S; Munshi A; Vijaykumar DK; Puri A; Mathew B; Arora RS; Kumari T P; Deodhar K; Menon S; Epari S; Shetty O; Cluzeau F
BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35985695
[TBL] [Abstract][Full Text] [Related]
13. Mind the gap: Mapping variation between national and local clinical practice guidelines for acute paediatric asthma from the United Kingdom and the Netherlands.
Koldeweij C; Appelbaum N; Rodriguez Gonzalvez C; Nijman J; Nijman R; Sinha R; Maconochie I; Clarke J
PLoS One; 2022; 17(5):e0267445. PubMed ID: 35580117
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of guideline-recommended medications prescribed for treatment of low back pain.
Price MR; Cupler ZA; Hawk C; Bednarz EM; Walters SA; Daniels CJ
Chiropr Man Therap; 2022 May; 30(1):26. PubMed ID: 35562756
[TBL] [Abstract][Full Text] [Related]
15. Methodological issues in economic evaluations of emergency transport systems in low-income and middle-income countries.
Lilford R; Nepogodiev D; Chilton PJ; Watson SI; Erlangga D; Diggle P; Girling AJ; Sculpher M
BMJ Glob Health; 2021 Mar; 6(3):. PubMed ID: 33737285
[TBL] [Abstract][Full Text] [Related]
16. What Role Can Process Mining Play in Recurrent Clinical Guidelines Issues? A Position Paper.
Gatta R; Vallati M; Fernandez-Llatas C; Martinez-Millana A; Orini S; Sacchi L; Lenkowicz J; Marcos M; Munoz-Gama J; Cuendet MA; de Bari B; Marco-Ruiz L; Stefanini A; Valero-Ramon Z; Michielin O; Lapinskas T; Montvila A; Martin N; Tavazzi E; Castellano M
Int J Environ Res Public Health; 2020 Sep; 17(18):. PubMed ID: 32932877
[TBL] [Abstract][Full Text] [Related]
17. Prioritising, Ranking and Resource Implementation - A Normative Analysis.
Sandman L
Int J Health Policy Manag; 2018 Jun; 7(6):532-541. PubMed ID: 29935130
[TBL] [Abstract][Full Text] [Related]
18. Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.
Harvard S; Guh D; Bansback N; Richette P; Saraux A; Fautrel B; Anis A
Cost Eff Resour Alloc; 2017; 15():20. PubMed ID: 28904528
[TBL] [Abstract][Full Text] [Related]
19. Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
Drummond M
Value Health; 2016; 19(5):525-30. PubMed ID: 27565268
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
